Background
Methods
Search Strategy
Eligibility criteria
Inclusion criteria
Exclusion criteria
Screening and data extraction
Quality assessment of the included studies
Statistical analysis
Results
Literature retrieval and screening
Characteristics of included articles
Authors | Year | Country | Sample used | Patient Characteristics | Diagnosis | Screening method | Validation method | Biomarker utility | miRNA profile | Labeling for RF plot | Group definition for RF plot | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Control | Male/Female | Age | Cases | Male/Female | Age | |||||||||||
Abd-El-Fattah et al., | 2013 | Mexico | Serum | 37 HC | 21/16 | 50.1 ± 14.2 | 29 PTB | 17/12 | 47.7 ± 9.8 | TST | qRT-PCR | HC vs. PTB | miR-197↑ | A | HC vs. TB | |
Carranza C et al., | 2021 | North Western China | Serum (Exosomes) | 15 HC | 10/5 | 45 (27–61) | 24 DR-TB | 18/11 | 43.5 (19–77) | PTB: Confirmed diagnosis of TB and were under Directly Observed Therapy | TaqMan RT-qPCR | TaqMan Advanced miRNA assays | HC vs. DR-TB | miR-197-3p↓ | B | HC vs. TB |
miR-223-3p↓ | C | HC vs. TB | ||||||||||||||
miR-let7e-5p↑ | D | HC vs. TB | ||||||||||||||
miRs(197-3p + let-7e-5p +223-3p) (Differential expression) | E | HC vs. TB | ||||||||||||||
HC vs. MDR-TB | miR-197-3p↓ | F | HC vs. TB | |||||||||||||
miR-223-3p ↓ | G | HC vs. TB | ||||||||||||||
miR-let7e-5p↑ | H | HC vs. TB | ||||||||||||||
miRs(197-3p + let-7e-5p +223-3p) (Differential expression) | I | HC vs. TB | ||||||||||||||
EN Ndzi et al., | 2019 | Cameroon | Plasma | 43 HC | 13/29 | 27 ± 7 | 84 PTB 35 LTB | PTB: 57/26 LTB: 8/27 | PTB: 33 ± 12 LTB: 34 ± 11 | PTB: Microscopy or culture (0, 2, 6) LTB: Positive QFT HC: Negative QFT | Database reported miRNAs | miRCURY LNA SYBR Green PCR kit (Qiagen, Maryland, USA) | HC vs. PTB | hsa-miR-29a-3p↑ | J | HC vs. TB |
hsa-miR-361-5p↑ | K | HC vs. TB | ||||||||||||||
LTB vs. PTB | hsa-miR-29a-3p↑ | L | LTB vs. TB | |||||||||||||
hsa-miR-361-5p↑ | M | LTB vs. TB | ||||||||||||||
Huihui Tu et al., | 2019 | China | Serum | 86 HC | 50/36 | 21-64 | 108 PTB | 66/42 | 18-72 | PTB: Diagnostic criteria of the Ministry of Health, China | Solexa sequencing | SYBR green qRT-PCR | HC vs. PTB | miR-17- 5p, miR-20b-5p, miR-423-5p↑ | N | HC vs. TB |
SE Barry et al., | 2018 | Egypt | Plasma | 100 HC | 57/43 | 35 (18-78) | 100 PTB | 58/42 | 43 (19-91) | PTB: Clinical and radiographic findings and sputum smear microscopy and mycobacterial culture HC: Interview and chest radiography | Plasma Focus miRNA PCR Panels (Exiqon) | qRT-PCR (Exiqon) | HC vs. PTB | miR-29a, miR-99b, miR-21, miR-146a, miR-652 (Differential expression) | O | HC vs. TB |
Yan Lv et al., | 2015 | China | Serum | 117 HC | 70/47 | 27.49 ± 8.80 | 124 PTB | 70/54 | 27.25 ± 8.99 | PTB: Typical TB clinical symptoms, bacterial culture, and imaging examinations | qRT-PCR | HC vs. PTB | miR-144↑ | P | HC vs. TB | |
Xing Zhang et al. | 2013 | China | Serum | 88 HC | 65/23 | 48 (24–67) | 108 PTB | 73/35 | 45 (14–62) | PTB: clinical manifestations, bacterial culture, and radiographic findings | SYBR green qRT-PCR assay | HC vs. PTB | hsa-miR-378↓ | Q | HC vs. TB | |
hsa-miR-483-5p↓ | R | HC vs. TB | ||||||||||||||
hsa-miR-22↓ | S | HC vs. TB | ||||||||||||||
hsa-miR-29c↓ | T | HC vs. TB | ||||||||||||||
hsa-miR-101↑ | U | HC vs. TB | ||||||||||||||
hsa-miR-320b↑ | V | HC vs. TB | ||||||||||||||
hsa-miR-378, hsa-miR-483-5p, hsa-miR-22, hsa-miR-29c, hsa-miR-101, hsa-miR-320b (Differential expression) | W | HC vs. TB |